News
VTRS
11.66
+0.09%
0.01
Viatris (VTRS): Assessing Valuation After a Recent Share Price Rebound
Simply Wall St · 1h ago
Weekly Report: what happened at VTRS last week (1208-1212)?
Weekly Report · 14h ago
Is Viatris Stock Outperforming the Dow?
Barchart · 14h ago
Notable healthcare headlines for the week: CVS, Eli Lilly and Novartis in focus
Seeking Alpha · 1d ago
Viatris Initiated at Overweight by Barclays
Dow Jones · 6d ago
Barclays Initiates Coverage On Viatris with Overweight Rating, Announces Price Target of $15
Benzinga · 6d ago
Here's 12 Ideal 'Safer' December Dividend Dogs Of The S&P500
Seeking Alpha · 6d ago
Analysts Offer Insights on Healthcare Companies: Viatris (VTRS), Agios Pharma (AGIO) and Phreesia (PHR)
TipRanks · 6d ago
VIATRIS INC. <VTRS.O>:  BARCLAYS INITIATES COVERAGE WITH OVERWEIGHT RATING AND TARGET PRICE $15
Reuters · 6d ago
Viatris initiated with an Overweight at Barclays
TipRanks · 12/08 21:30
Viatris Sells Biocon Biologics Stake to Biocon for $815 Million
Reuters · 12/08 12:01
Viatris sells Biocon Biologics stake for $815 million in cash and equity deal
Seeking Alpha · 12/08 09:50
Weekly Report: what happened at VTRS last week (1201-1205)?
Weekly Report · 12/08 09:42
Viatris to sell equity stake in Biocon Biologics to Biocon for $815M
TipRanks · 12/07 17:45
Viatris To Sell Equity Stake In Biocon Biologics To Biocon For $815 Mln
NASDAQ · 12/06 14:17
Viatris Sells Biocon Biologics Stake to Biocon for $815 Million
Reuters · 12/06 14:00
RPT: VIATRIS ANNOUNCES AGREEMENT TO MONETIZE ITS EQUITY STAKE IN BIOCON BIOLOGICS LIMITED
Reuters · 12/06 14:00
Press Release: Viatris Announces Agreement to Monetize its Equity Stake in Biocon Biologics Limited
Dow Jones · 12/06 14:00
CORRECTED-UPDATE 1-India's Biocon to make Biocon Biologics a wholly owned subsidiary
Reuters · 12/06 06:21
Viatris Holds Annual Shareholder Meeting on December 5
TipRanks · 12/05 21:49
More
Webull provides a variety of real-time VTRS stock news. You can receive the latest news about Viatris Inc Ord Shs through multiple platforms. This information may help you make smarter investment decisions.
About VTRS
Viatris Inc. is a global healthcare company. The Company's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. The Developed Markets segment comprises its operations primarily in North America and Europe. The Greater China segment includes its operations in China, Taiwan and Hong Kong. The JANZ segment reflects its operations in Japan, Australia, and New Zealand. The Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies, including in Asia, Africa, Eastern Europe, Latin America, and the Middle East, as well as the Company’s Antiretroviral medicines (ARV) franchise. Its pipeline and research and development capabilities include expertise in formulation, device development, toxicology, analytical, clinical, bioanalytical, medical affairs, product safety and risk management across a range of therapeutic areas. It produces oral solid doses, injectables, and products with complex dosage forms.